ArticleOncogene2001
Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance.
Article in Oncogene, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 123 citations in OpenAlex.
- Secreted frizzled-related protein 2 monoclonal antibody-mediated IFN-ϒ reprograms tumor-associated macrophages to suppress triple negative breast cancer.Breast cancer research : BCR · 2025Article
- STK32C modulates doxorubicin resistance in triple-negative breast cancer cells via glycolysis regulation.Molecular and cellular biochemistry · 2025Article
- Article
- cRGD-Peptide Modified Covalent Organic Frameworks for Precision Chemotherapy in Triple-Negative Breast Cancer.ACS applied materials & interfaces · 2024Article
- Continuous exposure to doxorubicin induces stem cell-like characteristics and plasticity in MDA-MB-231 breast cancer cells identified with the SORE6 reporter.Cancer chemotherapy and pharmacology · 2024Article
- Intertumoral and intratumoral barriers as approaches for drug delivery and theranostics to solid tumors using stimuli-responsive materials.Mikrochimica acta · 2024Review
- Article
- PFDN4 as a Prognostic Marker Was Associated with Chemotherapy Resistance through CREBP1/AURKA Pathway in Triple-Negative Breast Cancer.International journal of molecular sciences · 2024Article
- Article
- Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling.International journal of molecular sciences · 2021Article
- Review
- LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.Journal of cellular and molecular medicine · 2020Article
- Prospect and challenge of detecting dynamic gene copy number increases in stem cells by whole genome sequencing.Journal of molecular medicine (Berlin, Germany) · 2019Article
- Chemotherapy resistance and stemness in mitotically quiescent human breast cancer cells identified by fluorescent dye retention.Clinical & experimental metastasis · 2018Article
- SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer.Journal of experimental & clinical cancer research : CR · 2018Article
- Genetic background influences susceptibility to chemotherapy-induced hematotoxicity.The pharmacogenomics journal · 2018Article
- Efflux inhibition by IWR-1-endo confers sensitivity to doxorubicin effects in osteosarcoma cells.Biochemical pharmacology · 2018Article
- Genomic amplification of chromosome 7 in the Doxorubicin resistant K562 cell line.Bioinformation · 2018Article
- Exostosin 1 regulates cancer cell stemness in doxorubicin-resistant breast cancer cells.Oncotarget · 2017Article
- Detecting Disease Specific Pathway Substructures through an Integrated Systems Biology Approach.Non-coding RNA · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The multidrug resistance (MDR) phenotype is a major cause of cancer treatment failure. Here the expressions of 4224 genes were analysed for association with intrinsic or acquired doxorubicin (DOX) resistance. A cluster of overexpressed genes related to DOX resistance was observed. Included in this cluster was ABCB1 the P-glycoprotein transporter protein gene and MMP1 (Matrix Metalloproteinase 1), indicative of the invasive nature of resistant cells, and the oxytocin receptor (OXTR), a potential new therapeutic target. Overexpression of genes associated with xenobiotic transformation, cell transformation, cell signalling and lymphocyte activation was also associated with DOX resistance as was estrogen receptor negativity. In all carcinoma cells, compared with HBL100 a putatively normal breast epithelial cell line, a cluster of overexpressed genes was identified which included several keratins, in particular keratins 8 and 18 which are regulated through the ras signalling pathway. Analysis of genomic amplifications and deletions revealed specific genetic alterations common to both intrinsic and acquired DOX resistance including ABCB1, PGY3 (ABCB4) and BAK. The findings shown here indicate new possibilities for the diagnosis of DOX resistance using gene expression, and potential novel therapeutic targets for pharmacological intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.